Blinatumomab

Multispecific antibody

Approvedregulatory verdict

Evidence outlook

Approved: Acute Lymphoblastic Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Rheumatoid Arthritis · Phase 2Systemic Lupus Erythematosus · Phase 2

Also approved (4)
US
  • MRD-positive B-cell Precursor ALL BLINCYTO is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adult and pediatric patients one month and older.
  • Relapsed or Refractory B-cell Precursor ALL BLINCYTO is indicated for the treatment of relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older.
Product first approved 2014Outside this platform's coverageFDA label
JP
  • Relapsed or refractory B-cell acute lymphoblastic leukemia
Product first approved 2018amgen.com
EU
  • CD19 positive relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in adults (Blincyto; conditional marketing authorisation)
Product first approved 2015EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (16)
Acute Lymphoblastic Leukemia
NCT07223190 · Amgen
2028-06-30 – 2035-08-29 · Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia
What this study did
NCT03959085 · Children's Oncology Group
2019-10-31 – 2032-03-31 · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
What this study did
NCT04994717 · Amgen
2021-11-02 – 2031-06-30 · Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
What this study did
NCT05327894 · Princess Maxima Center for Pediatric Oncology
2022-12-15 – 2030-09 · Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
What this study did
NCT07723911 · Institute of Hematology & Blood Diseases Hospital, China
2026-08-09 – 2028-10-10 · Precursor B-cell Acute Lymphoblastic Leukemia
What this study did
NCT03643276 · Martin Schrappe
2018-07-15 – 2028-07-14 · Acute Lymphoblastic Leukemia, Pediatric
What this study did
NCT04530565 · National Cancer Institute (NCI)
2021-01-25 – 2028-07-01 · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
What this study did
NCT03914625 · National Cancer Institute (NCI)
2019-07-03 – 2027-09-30 · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome
What this study did
NCT02101853 · National Cancer Institute (NCI)
2014-12-17 – 2027-09-16 · Recurrent B Acute Lymphoblastic Leukemia
What this study did
NCT04722848 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2021-09-08 – 2027-09 · Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL
What this study did
Other / comorbidity
NCT04307576 · Mats Heyman
2020-07-13 – 2033-06 · Leukemia, Acute Lymphoblastic
What this study did
NCT07476729 · Charite University, Berlin, Germany
2026-09-01 – 2033-03-31 · B-Cell Acute Lymphoblastic Leukaemia
What this study did
Phase 2/3 (8)
Acute Lymphoblastic Leukemia
NCT06860269 · Assistance Publique - Hôpitaux de Paris
2025-05-06 – 2035-03-15 · Acute Lymphoblastic Leukemia
What this study did
NCT06882057 · Institute of Hematology & Blood Diseases Hospital, China
2025-03-03 – 2033-06 · Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
What this study did
NCT06764238 · Institute of Hematology & Blood Diseases Hospital, China
2025-01-03 – 2031-06 · Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
What this study did
NCT03117751 · St. Jude Children's Research Hospital
2017-03-29 – 2028-09-30 · Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
What this study did
Other / comorbidity
NCT06607419 · Shanghai Jiao Tong University School of Medicine
2024-05-21 – 2030-05-31 · B-Cell Lymphoblastic Leukemia
What this study did
NCT06836973 · Da, Yuwei, M.D.
2025-04-01 – 2028-06-30 · Myasthenia Gravis
What this study did
NCT06684184 · Zhongming Qiu
2024-11-30 – 2026-06-30 · Myasthaenia Gravis
What this study did
NCT02910063 · Amgen
2017-01-23 – 2020-03-12 · B-Cell Non Hodgkin Lymphoma
What this study did
Phase 2 (78)
Acute Lymphoblastic Leukemia
NCT07227584 · Dana-Farber Cancer Institute
2026-04-03 – 2035-07-31 · Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Leukemia
What this study did
NCT06533748 · St. Jude Children's Research Hospital
2025-01-23 – 2034-05 · Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
What this study did
NCT07178912 · M.D. Anderson Cancer Center
2027-01-27 – 2033-09-30 · Phase II Clinical Trial, Blinatumomab, Olverembatinib, Lymphoblastic Leukemia, Philadelphia Chromosome Positive
What this study did
NCT05827549 · Ho Joon Im
2024-04-04 – 2032-12-31 · Acute Lymphoid Leukemia
What this study did
NCT07192237 · M.D. Anderson Cancer Center
2026-04-21 – 2032-10-12 · Phase 2 Study, Blinatumomab, Acute Lymphoblastic Leukemia
What this study did
NCT07636564 · SWOG Cancer Research Network
2026-10-14 – 2032-04-16 · Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
What this study did
NCT07301424 · University of Alberta
2027-01-02 – 2031-12 · Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic Leukemia
What this study did
NCT07643103 · Institute of Hematology & Blood Diseases Hospital, China
2026-06-12 – 2030-05-31 · Ph- Acute Lymphoblastic Leukemia (Ph-ALL)
What this study did
NCT07840976 · Institute of Hematology & Blood Diseases Hospital, China
2026-10-12 – 2030-05-31 · Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)
What this study did
NCT04746209 · Medical College of Wisconsin
2021-02-01 – 2029-12-31 · B-cell Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-Cell ALL, Childhood
What this study did
NCT06061094 · Goethe University
2023-07-14 – 2029-07-01 · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
What this study did
NCT07199855 · Zhejiang University
2025-06-01 – 2029-07-01 · B-Cell Acute Lymphoblastic Leukemia, Adult
What this study did
NCT06317662 · National Cancer Institute (NCI)
2025-06-05 – 2028-12-31 · Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
What this study did
NCT02877303 · M.D. Anderson Cancer Center
2016-11-01 – 2028-11-01 · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
What this study did
NCT03709719 · Assistance Publique - Hôpitaux de Paris
2018-10-20 – 2028-10-30 · Acute Lymphoblastic Leukemia, Adult B-Cell
What this study did
NCT06742515 · First Affiliated Hospital of Zhejiang University
2024-10-17 – 2028-08-31 · Precursor B-Cell Acute Lymphoblastic Leukemia
What this study did
NCT06438796 · Ruijin Hospital
2024-07-01 – 2028-07-01 · High Risk Acute Lymphoblastic Leukemia
What this study did
NCT07564453 · The First Affiliated Hospital of Soochow University
2025-04-01 – 2028-06-30 · B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
What this study did
NCT04546399 · National Cancer Institute (NCI)
2020-12-17 – 2028-06-30 · Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
What this study did
NCT06220487 · Nanfang Hospital, Southern Medical University
2024-02-01 – 2028-01-01 · Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Philadelphia-Positive ALL, Adult ALL, IKZF1 Gene Mutation
What this study did
NCT06985485 · The First Affiliated Hospital of Soochow University
2025-05-17 – 2027-12-31 · Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab, Inotuzumab Ozogamicin
What this study did
NCT03849651 · St. Jude Children's Research Hospital
2019-01-31 – 2027-12-31 · Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), NK-Cell Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma (NHL), Juvenile Myelomonocytic Leukemia (JMML), Chronic Myeloid Leukemia (CML)
What this study did
NCT03263572 · M.D. Anderson Cancer Center
2017-11-29 – 2027-11-30 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, t(9;22)
What this study did
NCT06054113 · Amgen
2024-07-23 – 2027-10-14 · B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
What this study did
NCT02143414 · National Cancer Institute (NCI)
2015-06-30 – 2027-06-06 · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
What this study did
NCT05519579 · Northside Hospital, Inc.
2023-06-30 – 2027-06-01 · Acute Lymphoblastic Leukemia
What this study did
NCT06886074 · Hospital Universitario Dr. Jose E. Gonzalez
2025-01-02 – 2027-06 · Acute Lymphoblastic Leukemia, Measurable Residual Disease (MRD)
What this study did
NCT06393985 · The First Affiliated Hospital of Soochow University
2024-04-25 – 2027-04-25 · B-cell Acute Lymphoblastic Leukemia
What this study did
NCT04329325 · Memorial Sloan Kettering Cancer Center
2020-03-30 – 2027-03 · Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive
What this study did
NCT03147612 · M.D. Anderson Cancer Center
2018-02-08 – 2027-02-28 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
What this study did
NCT03739814 · National Cancer Institute (NCI)
2019-05-08 – 2027-02-01 · B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
What this study did
NCT03541083 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2018-06-04 – 2026-12-15 · ALL, Adult
What this study did
NCT02790515 · St. Jude Children's Research Hospital
2016-07-14 – 2026-07-01 · Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
What this study did
NCT04688983 · Cardiff University
2021-01 – 2026-01 · Acute Lymphoblastic Leukemia, Adult
What this study did
NCT05559450 · The First Affiliated Hospital of Soochow University
2022-02-01 – 2026-01 · B-cell Acute Lymphoblastic Leukemia
What this study did
NCT02458014 · M.D. Anderson Cancer Center
2015-09-14 – 2025-09-16 · Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Philadelphia Chromosome Positive
What this study did
NCT02997761 · University of California, Davis
2017-06-27 – 2025-07-17 · Adult B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
What this study did
NCT03367299 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2018-06-08 – 2024-09-02 · Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor
What this study did
NCT05557110 · Chen Suning
2022-09-08 – 2024-03-31 · B Acute Lymphoblastic Leukemia
What this study did
NCT04554485 · Institute of Hematology and Blood Transfusion, Czech Republic
2019-05-09 – 2024-02-29 · Lymphoblastic Leukemia, Acute, Adult, Ph Negative ALL, Newly Diagnosed
What this study did
NCT04448834 · Dorothy Sipkins, MD, PhD
2022-01 – 2023-06-01 · B-cell Acute Lymphoblastic Leukemia
What this study did
NCT03109093 · Goethe University
2017-03-15 – 2023-03-10 · ALL, Recurrent, Adult
What this study did
NCT04556084 · Michael Burke
2021-01-01 – 2022-10-01 · B-cell Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia
What this study did
NCT04044560 · University of British Columbia
2020-09-08 – 2022-02-02 · B-cell Adult Acute Lymphoblastic Leukemia, Stem Cell Leukemia, Minimal Residual Disease
What this study did
NCT02807883 · M.D. Anderson Cancer Center
2016-08 – 2022-02-01 · Acute Lymphoblastic Leukemia
What this study did
NCT03982992 · Ludwig-Maximilians - University of Munich
2019-06-01 – 2021-11-30 · B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation, B-Cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Lymphoblastic Leukemia, Adult
What this study did
NCT02744768 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2017-05-31 – 2021-06 · Acute Lymphoblastic Leukemia
What this study did
NCT03518112 · M.D. Anderson Cancer Center
2018-04-18 – 2021-05-27 · Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
What this study did
Phase 1/2 (19)
Acute Lymphoblastic Leukemia
NCT07387926 · Novartis Pharmaceuticals
2026-07-05 – 2036-05-30 · Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
What this study did
NCT05848687 · Tanja Andrea Gruber
2023-11-03 – 2033-12 · Lymphoblastic Leukemia
What this study did
NCT07153796 · M.D. Anderson Cancer Center
2026-01-30 – 2033-09-30 · B-cell Acute Lymphoblastic Leukemia
What this study did
NCT07134088 · Amgen
2025-12-08 – 2032-09-16 · Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
What this study did
NCT04521231 · Amgen
2021-01-04 – 2029-05-25 · B Cell Precursor Acute Lymphoblastic Leukemia
What this study did
NCT06308588 · M.D. Anderson Cancer Center
2024-08-05 – 2029-05-01 · Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia
What this study did
NCT07313852 · Memorial Sloan Kettering Cancer Center
2026-12 – 2029-01 · B-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult, B-ALL
What this study did
NCT01371630 · M.D. Anderson Cancer Center
2011-08-26 – 2027-12-25 · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Burkitt-Like Lymphoma With 11q Aberration, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Burkitt Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Burkitt Lymphoma
What this study did
NCT03512405 · City of Hope Medical Center
2019-08-02 – 2027-09-29 · CD19 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
What this study did
NCT05192889 · St. Jude Children's Research Hospital
2022-08-25 – 2027-02 · Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
What this study did
NCT03114865 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2017-09-05 – 2026-12-30 · Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma, Pre B-Cell Acute Lymphoblastic Leukaemia
What this study did
NCT03160079 · University of California, San Diego
2017-08-04 – 2023-06-23 · B-Cell Acute Lymphoblastic Leukemia, Adult
What this study did
NCT02412306 · Amgen
2015-06-04 – 2019-07-04 · Relapsed Refractory B Precursor Acute Lymphoblastic Leukemia
What this study did
Other / comorbidity
NCT07604233 · M.D. Anderson Cancer Center
2026-11-30 – 2033-06-03 · Myeloid Leukemia
What this study did
NCT07294677 · University of Chicago
2026-03-17 – 2032-03 · Leukemia, Lymphoma
What this study did
Phase 1 (29)
Acute Lymphoblastic Leukemia
NCT07283640 · M.D. Anderson Cancer Center
2026-11-18 – 2031-08-31 · Blinatumomab, Revumenib, Lymphoblastic Leukemia, KMT2A-rearranged
What this study did
NCT06507514 · The First Affiliated Hospital of Soochow University
2024-04-01 – 2030-04-01 · B-cell Acute Lymphoblastic Leukemia
What this study did
NCT04260022 · Ascentage Pharma Group Inc.
2020-01-09 – 2030-03-31 · Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia
What this study did
NCT07914166 · City of Hope Medical Center
2027-10-13 – 2028-10-13 · B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
What this study did
NCT07133997 · City of Hope Medical Center
2026-05-13 – 2028-06-01 · Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
What this study did
NCT04872790 · OHSU Knight Cancer Institute
2022-09-02 – 2027-12-02 · B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia
What this study did
NCT03595917 · Marlise Luskin, MD
2018-07-24 – 2027-11-01 · B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
What this study did
NCT02879695 · National Cancer Institute (NCI)
2017-10-25 – 2027-07-18 · Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Mixed Phenotype Acute Leukemia
What this study did
NCT06649006 · Amgen
2025-01-08 – 2025-12-04 · B-precursor Acute Lymphoblastic Leukemia
What this study did
NCT04604691 · Seoul National University Hospital
2022-02-18 – 2024-12 · Pediatric ALL, B Cell, Minimal Residual Disease
What this study did
NCT04524455 · Amgen
2020-10-02 – 2023-01-24 · Acute Lymphoblastic Leukemia
What this study did
Systemic Lupus Erythematosus
Other / comorbidity
NCT07869368 · UNC Lineberger Comprehensive Cancer Center
2026-12 – 2030-02 · B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia), Philadelphia Chromosome-Negative Lymphoblastic Leukemia, CD19-positive B-cell Acute
What this study did
NCT07706205 · West China Hospital
2026-09-01 – 2028-12-31 · ABO Blood Type Incompatible Kidney Transplantation
What this study did
NCT07677878 · Liping Dou
2024-12-01 – 2028-12-01 · ALL (Acute B-Lymphoblastic Leukemia)
What this study did
NCT06607991 · The Children's Hospital of Zhejiang University School of Medicine
2024-09-19 – 2027-09-18 · CNI-resistant Steriod Resistant Nephrotic Syndrome, CNI-intolerent, Steriod Resistant Nephrotic Syndrome, Multidrug Resistant Nephrotic Syndrome
What this study did
NCT06063317 · Imugene Limited
2023-10-02 – 2026-02-02 · Solid Tumor, Adult
What this study did
NCT02568553 · National Cancer Institute (NCI)
2016-11-15 – 2025-11-24 · Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent Gray-Zone Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mediastinal Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Gray-Zone Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Mediastinal Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
What this study did
NCT03751709 · Cedars-Sinai Medical Center
2020-02-14 – 2024-11-12 · B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult, B-ALL
What this study did
NCT03072771 · Washington University School of Medicine
2017-08-01 – 2023-10-30 · Diffuse Large B Cell Lymphoma
What this study did
NCT03340766 · Amgen
2018-03-16 – 2023-08-14 · Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
What this study did
NCT03823365 · A.O. Ospedale Papa Giovanni XXIII
2018-12-17 – 2022-11 · Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia
What this study did
NCT03605589 · Children's Hospital Medical Center, Cincinnati
2018-09-27 – 2022-01 · Leukemia, B-cell, Lymphoma, B-Cell
What this study did
NCT03173430 · Abramson Cancer Center at Penn Medicine
2017-05-27 – 2019-01-28 · Multiple Myeloma
What this study did
NCT00274742 · Amgen Research (Munich) GmbH
2004-06 – 2012-04 · Non-Hodgkin's Lymphoma, Relapsed
What this study did
NCT00538096 · MedImmune LLC
2007-09 – 2010-05 · Lymphoma, B-Cell, Lymphoma, Non-Hodgkin
What this study did
Phase 4 (3)
Acute Lymphoblastic Leukemia
NCT04506086 · Amgen
2021-08-26 – 2024-09-16 · B-precursor Acute Lymphoblastic Leukemia
What this study did
Other / comorbidity
NCT07686042 · Beijing Tiantan Hospital
2026-06-24 – 2028-12-31 · Autoimmune Encephalitis (AE), Autoimmune Cerebellitis
What this study did
NCT06339775 · Suping ZHANG
2023-09-01 – 2027-06-30 · Acute B-cell Lymphoblastic Leukemia
What this study did
Early phase / not applicable (12)
Acute Lymphoblastic Leukemia
NCT07443592 · PETHEMA Foundation
2026-03-06 – 2033-06-01 · Acute Lymphoblastic Leukemia
What this study did
NCT06763302 · The Children's Hospital of Zhejiang University School of Medicine
2025-01-01 – 2030-12-31 · B Cell Precursor Acute Lymphoblastic Leukemia, Pediatric, Minimal Residual Disease, Next Generation Sequencing (NGS)
What this study did
NCT07454226 · Institute of Hematology & Blood Diseases Hospital, China
2026-05-30 – 2030-03-01 · Ph-Like, Acute Lymphoblastic Leukemia
What this study did
NCT07495631 · Institute of Hematology & Blood Diseases Hospital, China
2026-04-08 – 2030-03-01 · Acute Lymphoblastic Leukemia, Adult
What this study did
NCT07003737 · First Affiliated Hospital of Zhejiang University
2025-02-05 – 2028-02-05 · Acute Lymphoblastic Leukemia, B-precursor
What this study did
NCT06237192 · National Research Center for Hematology, Russia
2023-04-01 – 2027-09-01 · Precursor Cell Lymphoblastic Leukemia-Lymphoma
What this study did
NCT06658938 · Institute of Hematology & Blood Diseases Hospital, China
2024-11-01 – 2026-10-01 · B-ALL
What this study did
NCT04723342 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2020-02-01 – 2025-12 · Childhood Acute Lymphoblastic Leukemia
What this study did
Other / comorbidity
NCT07921550 · Institute of Hematology & Blood Diseases Hospital, China
2026-11-30 – 2035-11-30 · ALL
What this study did
NCT06991920 · Institute of Hematology & Blood Diseases Hospital, China
2026-06-30 – 2032-04-01 · Adult ALL, MPAL
What this study did
NCT07493161 · Institute of Hematology & Blood Diseases Hospital, China
2026-04-10 – 2030-03-30 · Ph+ ALL
What this study did
NCT06504186 · Institute of Hematology & Blood Diseases Hospital, China
2024-07 – 2026-10 · B-ALL
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Acute Lymphoblastic Leukemia
NCT03628053 · Novartis Pharmaceuticals
2020-06-05 – 2026-01-07 · Acute Lymphoblastic Leukemia
What this study did
Phase 2/3 (2)
Acute Lymphoblastic Leukemia
NCT07570173 · Merck Sharp & Dohme LLC
2026-05-18 – 2033-10-18 · B-cell Acute Lymphoblastic Leukemia
What this study did
NCT07297914 · Bambino Gesù Hospital and Research Institute
2026-01-07 – 2032-12-01 · Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant, Graft -Versus-host-disease
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Acute Lymphoblastic Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Blinatumomab: this drugApprovedMultispecific antibodyCD19 x CD3Weak signal
NCT03476239: Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2 Treatment Cycles With Blinatumomab (Within 2 cycles of treatment (12 weeks)): Blinatumomab — Interim Analysis: 45.6 percentage of participants (95% CI 35 to 56.4); Final Analysis: 48.3 percentage of participants (95% CI 39.1 to 57.6)
MethotrexateApprovedSmall moleculeDihydrofolate reductase (DHFR), Folate Analog Metabolic Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Obecabtagene Autoleucel (Aucatzyl)ApprovedCell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
Ponatinib (ICLUSIG)ApprovedSmall moleculeBCR-ABL (including T315I)Partial signalFeatured results are non-efficacy only in this race
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
ZiftomenibPhase 1/2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication
XmAb657
Phase 1(overall)
Multispecific antibodyCD19 x CD3
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(80 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Blinatumomab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 2Precursor Cell Lymphoblastic Leukemia-LymphomaRecruiting
Est. primary completion 2026-12-01 · NCT06387121 · CT.gov ↗
What to watch
Phase 1/2Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2026-12-30 · NCT03114865 · CT.gov ↗
What to watch
Phase 4Acute B-cell Lymphoblastic LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT06339775 · CT.gov ↗
What to watch
2027 (29)
January 2027 (1)
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-01 · NCT06886074 · CT.gov ↗
What to watch
February 2027 (4)
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-02-01 · NCT05519579 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-02-01 · NCT03739814 · CT.gov ↗
What to watch
Early phase / not applicableAcute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-02-05 · NCT07003737 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2027-02-28 · NCT03147612 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2027-03 · NCT04329325 · CT.gov ↗
What to watch
May 2027 (2)
Phase 1/2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-05-01 · NCT06308588 · CT.gov ↗
What to watch
Early phase / not applicableALLNot yet recruiting
Est. primary completion 2027-05-01 · NCT07921550 · CT.gov ↗
What to watch
June 2027 (2)
Phase 1Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2027-06-01 · NCT03595917 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2027-06-01 · NCT07199855 · CT.gov ↗
What to watch
September 2027 (3)
Phase 3Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2027-09 · NCT04722848 · CT.gov ↗
What to watch
Phase 3Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-09 · NCT05327894 · CT.gov ↗
What to watch
Phase 3Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2027-09-30 · NCT03914625 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Primary Sjögren's Syndrome (pSS)Not yet recruiting
Est. primary completion 2027-10-01 · NCT07852234 · CT.gov ↗
What to watch
Phase 3Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2027-10-10 · NCT07723911 · CT.gov ↗
What to watch
November 2027 (3)
Phase 2Acute Lymphoid Leukemia (ALL)Not yet recruiting
Est. primary completion 2027-11-01 · NCT06930105 · CT.gov ↗
What to watch
Phase 1/2Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2027-11-24 · NCT04521231 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-11-30 · NCT03263572 · CT.gov ↗
What to watch
December 2027 (11)
Phase 1Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2027-12-02 · NCT04872790 · CT.gov ↗
What to watch
Phase 1Systemic Lupus ErythematosusRecruiting
Est. primary completion 2027-12-07 · NCT06789107 · CT.gov ↗
What to watch
Phase 1/2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-12-25 · NCT01371630 · CT.gov ↗
What to watch
Phase 1ABO Blood Type Incompatible Kidney TransplantationNot yet recruiting
Est. primary completion 2027-12-31 · NCT07706205 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT07105579 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT06985485 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT07564453 · CT.gov ↗
What to watch
Phase 2Newly Diagnosed Mixed Phenotype Acute LeukemiaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07573670 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07301424 · CT.gov ↗
What to watch
Phase 2LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT05645718 · CT.gov ↗
What to watch
Early phase / not applicableAcute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2027-12-31 · NCT06763302 · CT.gov ↗
What to watch
2028 (21)
March 2028 (4)
Early phase / not applicableAcute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-03-01 · NCT07454226 · CT.gov ↗
What to watch
Early phase / not applicableAcute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-03-01 · NCT07495631 · CT.gov ↗
What to watch
Phase 2/3Myasthenia GravisNot yet recruiting
Est. primary completion 2028-03-31 · NCT06836973 · CT.gov ↗
What to watch
Early phase / not applicablePh+ ALLRecruiting
Est. primary completion 2028-03-31 · NCT07493161 · CT.gov ↗
What to watch
April 2028 (1)
Phase 1Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-04-01 · NCT06507514 · CT.gov ↗
What to watch
May 2028 (3)
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-05 · NCT06533748 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2028-05-31 · NCT07643103 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2028-05-31 · NCT07840976 · CT.gov ↗
What to watch
June 2028 (2)
Phase 1Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-06-01 · NCT07133997 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-06-30 · NCT04546399 · CT.gov ↗
What to watch
July 2028 (2)
Phase 3Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2028-07-01 · NCT04530565 · CT.gov ↗
What to watch
Phase 3Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-07-14 · NCT03643276 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Rheumatoid ArthritisRecruiting
Est. primary completion 2028-08-06 · NCT06570798 · CT.gov ↗
What to watch
October 2028 (1)
Phase 1Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2028-10-13 · NCT07914166 · CT.gov ↗
What to watch
November 2028 (2)
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-11-01 · NCT02877303 · CT.gov ↗
What to watch
Phase 1ALL (Acute B-Lymphoblastic Leukemia)Recruiting
Est. primary completion 2028-11-30 · NCT07677878 · CT.gov ↗
What to watch
December 2028 (5)
Phase 1Hematologic MalignancyRecruiting
Est. primary completion 2028-12 · NCT07052370 · CT.gov ↗
What to watch
Phase 1/2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-12 · NCT05848687 · CT.gov ↗
What to watch
Phase 1/2Relapsed/Refractory, B-cell Acute Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT06287229 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT06317662 · CT.gov ↗
What to watch
Phase 4Autoimmune Encephalitis (AE), Autoimmune CerebellitisNot yet recruiting
Est. primary completion 2028-12-31 · NCT07686042 · CT.gov ↗
What to watch
2029 (9)
January 2029 (1)
Phase 1/2Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2029-01 · NCT07313852 · CT.gov ↗
What to watch
February 2029 (1)
Phase 1B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia), Philadelphia Chromosome-Negative Lymphoblastic Leukemia, CD19-positive B-cell AcuteNot yet recruiting
Est. primary completion 2029-02 · NCT07869368 · CT.gov ↗
What to watch
July 2029 (1)
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2029-07-01 · NCT06061094 · CT.gov ↗
What to watch
August 2029 (2)
Phase 2CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)Recruiting
Est. primary completion 2029-08 · NCT07222579 · CT.gov ↗
What to watch
Phase 1Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2029-08-31 · NCT07283640 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2029-09-07 · NCT04994717 · CT.gov ↗
What to watch
December 2029 (3)
Phase 1Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2029-12-27 · NCT04260022 · CT.gov ↗
What to watch
Phase 2/3Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2029-12-31 · NCT06882057 · CT.gov ↗
What to watch
Phase 2/3Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2029-12-31 · NCT06764238 · CT.gov ↗
What to watch
2030 (4)
April 2030 (1)
Early phase / not applicableAdult ALL, MPALNot yet recruiting
Est. primary completion 2030-04-01 · NCT06991920 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2030-07-31 · NCT07227584 · CT.gov ↗
What to watch
October 2030 (1)
Phase 2Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2030-10-12 · NCT07192237 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2030-12-01 · NCT06124157 · CT.gov ↗
What to watch
2031 (7)
March 2031 (2)
Phase 1/2Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2031-03-06 · NCT07134088 · CT.gov ↗
What to watch
Early phase / not applicableAcute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2031-03-06 · NCT07443592 · CT.gov ↗
What to watch
April 2031 (1)
Phase 2Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2031-04-16 · NCT07636564 · CT.gov ↗
What to watch
June 2031 (1)
Phase 1/2Myeloid LeukemiaNot yet recruiting
Est. primary completion 2031-06-03 · NCT07604233 · CT.gov ↗
What to watch
September 2031 (2)
Phase 1/2Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2031-09-30 · NCT07153796 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2031-09-30 · NCT07178912 · CT.gov ↗
What to watch
December 2031 (1)
Phase 3Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2031-12-30 · NCT07223190 · CT.gov ↗
What to watch
2032 (3)
March 2032 (2)
Phase 1/2Leukemia, LymphomaRecruiting
Est. primary completion 2032-03 · NCT07294677 · CT.gov ↗
What to watch
Phase 3Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2032-03-31 · NCT03959085 · CT.gov ↗
What to watch
December 2032 (1)
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2032-12-31 · NCT05827549 · CT.gov ↗
What to watch
2033 (3)
March 2033 (1)
Phase 3B-Cell Acute Lymphoblastic LeukaemiaRecruiting
Est. primary completion 2033-03-31 · NCT07476729 · CT.gov ↗
What to watch
June 2033 (1)
Phase 3Leukemia, Acute LymphoblasticRecruiting
Est. primary completion 2033-06 · NCT04307576 · CT.gov ↗
What to watch
September 2033 (1)
Phase 1/2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2033-09-19 · NCT07387926 · CT.gov ↗
What to watch
2035 (1)
March 2035 (1)
Phase 2/3Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2035-03-15 · NCT06860269 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

29 January 2025ApprovalEuropean Commission approves BLINCYTO in consolidation phase of Ph-negative B-ALL
EU, EC · Source ↗